Filing summary
Source mismatch: The supplied filing is for MEI Pharma, Inc., a Form 10-Q for the quarter ended September 30, 2016. It does not match the request metadata identifying Lite Strategy, Inc. and 2015 Q1. The summary below reflects the supplied filing.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company. Its portfolio includes Pracinostat, ME-401 and ME-344. This unaudited report covers the three months ended September 30, 2016, compared with the three months ended September 30, 2015; the balance sheet compares September 30, 2016 with June 30, 2016. Interim results are not necessarily indicative of full-year results.
Key financial metrics
| Metric | Quarter ended Sep. 30, 2016 | Comparable 2015 period or prior balance-sheet date |
|---|---|---|
| Revenue | $1.096 million | None |
| Cost of R&D revenue | $1.094 million | None |
| R&D expense | $1.646 million | $2.816 million |
| General and administrative expense | $2.680 million | $1.830 million |
| Operating loss | $4.324 million | $4.646 million |
| Net loss | $4.270 million | $4.620 million |
| Net loss per share, basic and diluted | $0.12 | $0.13 |
| Net cash from (used in) operating activities | $8.773 million | $(5.761) million |
| Cash, cash equivalents and short-term investments | $58.901 million | $45.918 million at June 30, 2016 |
| Total assets / total liabilities | $61.045 million / $18.714 million | $47.164 million / $5.512 million at June 30, 2016 |
The company reported no debt balance in the supplied balance sheet. Revenue less its related cost was approximately $2,000; the filing does not present a conventional product gross margin. Operating cash flow was primarily supported by the $15 million Helsinn upfront payment and a $15.537 million increase in deferred revenue, rather than by operating profitability.
Material changes versus the prior comparable period
- Revenue of $1.096 million and related cost of $1.094 million arose under the Helsinn agreement; the comparable 2015 quarter had no revenue.
- R&D expense fell by $1.170 million, reflecting lower trial costs, a $1.0 million reduction in accrued clinical-trial estimates, and Helsinn taking primary responsibility for Pracinostat development funding.
- General and administrative expense rose by $0.850 million, primarily due to professional services associated with the Helsinn agreement.
- Net loss narrowed by $0.350 million. Operating cash flow moved from a $5.761 million outflow to an $8.773 million inflow, largely due to the Helsinn upfront payment and related deferred revenue.
- Cash, cash equivalents and short-term investments increased $12.983 million from June 30, 2016. The company also issued 2,616,431 shares to Helsinn Investment Fund SA for $5 million.
Outlook, commentary, risks and unusual items
- Helsinn agreement: Helsinn received an exclusive worldwide license to develop, manufacture and commercialize Pracinostat and is primarily responsible for funding global development and commercialization. MEI received a $15 million upfront payment and is due another $5 million upon the earlier of first patient dosing in the planned Phase III AML study or March 1, 2017. MEI is eligible for up to $444 million in regulatory and sales milestones plus royalties. License revenue was expected to be recognized after technology and data transfer, anticipated in fiscal Q2 2017; R&D-related revenue is recognized as activities are performed.
- Development outlook: The FDA granted Breakthrough Therapy Designation to Pracinostat plus azacitidine for certain newly diagnosed AML patients, and the company reported agreement with the FDA on the proposed Phase III design. Enrollment in a Helsinn-supported Phase II MDS study was anticipated in the first half of calendar 2017. ME-401 interim data was expected in calendar Q2 2017.
- Liquidity: Management said $58.9 million in cash, cash equivalents and short-term investments was expected to fund operations for at least the next 12 months. The company nevertheless expected operating losses and negative operating cash flows for the foreseeable future and anticipated seeking future financing or partnerships.
- Unusual estimate adjustment: MEI reduced accrued clinical-trial expenses by $1.0 million for Pracinostat and ME-344 based on revised expected vendor invoices.
- Contingencies and commitments: The company had accrued $700,000 for potential S*Bio milestone payments; additional milestones of up to $75.2 million could become payable if specified events occur. Office lease payments totaled $257,000 through June 30, 2017. Clinical-trial and consulting contracts are generally terminable but require payment for costs incurred through termination.
- Risks: The company cited the need for additional financing, clinical and regulatory uncertainty, reliance on collaborators and license counterparties, development delays or failures, commercialization risks, competition and intellectual-property risks. It reported no material change in risk factors from its 2016 annual report and no legal proceedings.
Most important facts to verify
- Confirm the intended issuer and period: the supplied filing is MEI Pharma’s quarter ended September 30, 2016, not Lite Strategy’s 2015 Q1.
- Verify the Helsinn payment conditions, timing of the additional $5 million, cost-sharing obligations, milestone and royalty terms, and the accounting treatment of deferred revenue.
- Assess whether the stated cash runway remains adequate against planned clinical spending, future financing needs and the possibility of delayed or unsuccessful trials.
- Review the basis for the $1.0 million clinical-trial accrual reduction and the $700,000 S*Bio accrual, along with potential additional contractual payments.
- Consider dilution: 2,616,431 shares were issued to Helsinn, and the filing reports substantial outstanding options, RSUs and warrants.